Cimetidine Therapy for Gastroesophageal Reflux Disease
In a Canadian multicenter trial, a new dosing regimen of cimetidine (Tagamet)—600 mg given twice a day—was compared with the standard regimen of 300 mg four times a day in 118 evaluable patients with endoscopically proved esophagitis. More than 90% of the patients evaluated had clinically moderate t...
Gespeichert in:
| Veröffentlicht in: | The Western journal of medicine 1985-11, Vol.143 (5), p.616-621 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 621 |
|---|---|
| container_issue | 5 |
| container_start_page | 616 |
| container_title | The Western journal of medicine |
| container_volume | 143 |
| creator | Archambault, André P. Farley, Alain Cleator, I. G. Hershfield, Noel Barry Navert, Henri Prokipchuk, E. J. Thomson, Alan B. R. |
| description | In a Canadian multicenter trial, a new dosing regimen of cimetidine (Tagamet)—600 mg given twice a day—was compared with the standard regimen of 300 mg four times a day in 118 evaluable patients with endoscopically proved esophagitis. More than 90% of the patients evaluated had clinically moderate to severe esophagitis. After four weeks of therapy, both regimens had significantly reduced the number of episodes and the severity and duration of the worst episodes of daytime and nighttime heartburn, as evaluated by visual analogue scales. After eight weeks of therapy, this improvement persisted. There was no difference between the regimens. Healing was observed endoscopically in 57% of patients receiving cimetidine 300 mg four times a day and in 55% of those receiving 600 mg twice a day. Side effects were infrequent and minor. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1306424</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3993295631</sourcerecordid><originalsourceid>FETCH-LOGICAL-i327t-19c39fbe6bca15a3ea535ac015b614255314b566366d8df88ca2969ba1b4b8b33</originalsourceid><addsrcrecordid>eNpVkF1LwzAUhoMoc05_glDwupA0H21uBKm6iVVB5sddOGnTLbNra9LK9u8tbAy9OhfPy_O-nCM0JiwWYSTj5BiNMZY0xIzwU3Tm_QpjzDiRIzSiEkvB8BiJ1K5NZwtbm2C-NA7abVA2LpiC71xjfNMuYWGgCl5NWfWb4NZ6A96co5MSKm8u9neC3u7v5ukszF6mD-lNFloaxV1IZE5lqY3QORAO1ACnHHJMuBaERZxTwjQXggpRJEWZJDlEUkgNRDOdaEon6HrnbXu9NkVu6s5BpVpn1-C2qgGr_pPaLtWi-VGEYsEiNgiu9gLXfPfGd2rV9K4eNisSx0wSlhA5pC7_1hz8-zcNPNxx6zuzOWBwX0rENObq-T1VH-mj-MxmT0rSX2t_dCY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1774914819</pqid></control><display><type>article</type><title>Cimetidine Therapy for Gastroesophageal Reflux Disease</title><source>MEDLINE</source><source>PubMed Central</source><creator>Archambault, André P. ; Farley, Alain ; Cleator, I. G. ; Hershfield, Noel Barry ; Navert, Henri ; Prokipchuk, E. J. ; Thomson, Alan B. R.</creator><creatorcontrib>Archambault, André P. ; Farley, Alain ; Cleator, I. G. ; Hershfield, Noel Barry ; Navert, Henri ; Prokipchuk, E. J. ; Thomson, Alan B. R.</creatorcontrib><description>In a Canadian multicenter trial, a new dosing regimen of cimetidine (Tagamet)—600 mg given twice a day—was compared with the standard regimen of 300 mg four times a day in 118 evaluable patients with endoscopically proved esophagitis. More than 90% of the patients evaluated had clinically moderate to severe esophagitis. After four weeks of therapy, both regimens had significantly reduced the number of episodes and the severity and duration of the worst episodes of daytime and nighttime heartburn, as evaluated by visual analogue scales. After eight weeks of therapy, this improvement persisted. There was no difference between the regimens. Healing was observed endoscopically in 57% of patients receiving cimetidine 300 mg four times a day and in 55% of those receiving 600 mg twice a day. Side effects were infrequent and minor.</description><identifier>ISSN: 0093-0415</identifier><identifier>EISSN: 1476-2978</identifier><identifier>PMID: 3909640</identifier><identifier>CODEN: WJMDA2</identifier><language>eng</language><publisher>United States: BMJ Publishing Group LTD</publisher><subject>Adult ; Cimetidine - administration & dosage ; Cimetidine - adverse effects ; Cimetidine - therapeutic use ; Clinical Investigation ; Clinical Trials as Topic ; Drug Administration Schedule ; Esophagitis - diagnosis ; Esophagitis - drug therapy ; Esophagoscopy ; Female ; Gastroesophageal Reflux - drug therapy ; Humans ; Male ; Middle Aged ; Random Allocation ; Time Factors</subject><ispartof>The Western journal of medicine, 1985-11, Vol.143 (5), p.616-621</ispartof><rights>Copyright BMJ Publishing Group LTD Nov 1985</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1306424/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1306424/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3909640$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Archambault, André P.</creatorcontrib><creatorcontrib>Farley, Alain</creatorcontrib><creatorcontrib>Cleator, I. G.</creatorcontrib><creatorcontrib>Hershfield, Noel Barry</creatorcontrib><creatorcontrib>Navert, Henri</creatorcontrib><creatorcontrib>Prokipchuk, E. J.</creatorcontrib><creatorcontrib>Thomson, Alan B. R.</creatorcontrib><title>Cimetidine Therapy for Gastroesophageal Reflux Disease</title><title>The Western journal of medicine</title><addtitle>West J Med</addtitle><description>In a Canadian multicenter trial, a new dosing regimen of cimetidine (Tagamet)—600 mg given twice a day—was compared with the standard regimen of 300 mg four times a day in 118 evaluable patients with endoscopically proved esophagitis. More than 90% of the patients evaluated had clinically moderate to severe esophagitis. After four weeks of therapy, both regimens had significantly reduced the number of episodes and the severity and duration of the worst episodes of daytime and nighttime heartburn, as evaluated by visual analogue scales. After eight weeks of therapy, this improvement persisted. There was no difference between the regimens. Healing was observed endoscopically in 57% of patients receiving cimetidine 300 mg four times a day and in 55% of those receiving 600 mg twice a day. Side effects were infrequent and minor.</description><subject>Adult</subject><subject>Cimetidine - administration & dosage</subject><subject>Cimetidine - adverse effects</subject><subject>Cimetidine - therapeutic use</subject><subject>Clinical Investigation</subject><subject>Clinical Trials as Topic</subject><subject>Drug Administration Schedule</subject><subject>Esophagitis - diagnosis</subject><subject>Esophagitis - drug therapy</subject><subject>Esophagoscopy</subject><subject>Female</subject><subject>Gastroesophageal Reflux - drug therapy</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Random Allocation</subject><subject>Time Factors</subject><issn>0093-0415</issn><issn>1476-2978</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1985</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpVkF1LwzAUhoMoc05_glDwupA0H21uBKm6iVVB5sddOGnTLbNra9LK9u8tbAy9OhfPy_O-nCM0JiwWYSTj5BiNMZY0xIzwU3Tm_QpjzDiRIzSiEkvB8BiJ1K5NZwtbm2C-NA7abVA2LpiC71xjfNMuYWGgCl5NWfWb4NZ6A96co5MSKm8u9neC3u7v5ukszF6mD-lNFloaxV1IZE5lqY3QORAO1ACnHHJMuBaERZxTwjQXggpRJEWZJDlEUkgNRDOdaEon6HrnbXu9NkVu6s5BpVpn1-C2qgGr_pPaLtWi-VGEYsEiNgiu9gLXfPfGd2rV9K4eNisSx0wSlhA5pC7_1hz8-zcNPNxx6zuzOWBwX0rENObq-T1VH-mj-MxmT0rSX2t_dCY</recordid><startdate>19851101</startdate><enddate>19851101</enddate><creator>Archambault, André P.</creator><creator>Farley, Alain</creator><creator>Cleator, I. G.</creator><creator>Hershfield, Noel Barry</creator><creator>Navert, Henri</creator><creator>Prokipchuk, E. J.</creator><creator>Thomson, Alan B. R.</creator><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>5PM</scope></search><sort><creationdate>19851101</creationdate><title>Cimetidine Therapy for Gastroesophageal Reflux Disease</title><author>Archambault, André P. ; Farley, Alain ; Cleator, I. G. ; Hershfield, Noel Barry ; Navert, Henri ; Prokipchuk, E. J. ; Thomson, Alan B. R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-i327t-19c39fbe6bca15a3ea535ac015b614255314b566366d8df88ca2969ba1b4b8b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1985</creationdate><topic>Adult</topic><topic>Cimetidine - administration & dosage</topic><topic>Cimetidine - adverse effects</topic><topic>Cimetidine - therapeutic use</topic><topic>Clinical Investigation</topic><topic>Clinical Trials as Topic</topic><topic>Drug Administration Schedule</topic><topic>Esophagitis - diagnosis</topic><topic>Esophagitis - drug therapy</topic><topic>Esophagoscopy</topic><topic>Female</topic><topic>Gastroesophageal Reflux - drug therapy</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Random Allocation</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Archambault, André P.</creatorcontrib><creatorcontrib>Farley, Alain</creatorcontrib><creatorcontrib>Cleator, I. G.</creatorcontrib><creatorcontrib>Hershfield, Noel Barry</creatorcontrib><creatorcontrib>Navert, Henri</creatorcontrib><creatorcontrib>Prokipchuk, E. J.</creatorcontrib><creatorcontrib>Thomson, Alan B. R.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Western journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Archambault, André P.</au><au>Farley, Alain</au><au>Cleator, I. G.</au><au>Hershfield, Noel Barry</au><au>Navert, Henri</au><au>Prokipchuk, E. J.</au><au>Thomson, Alan B. R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cimetidine Therapy for Gastroesophageal Reflux Disease</atitle><jtitle>The Western journal of medicine</jtitle><addtitle>West J Med</addtitle><date>1985-11-01</date><risdate>1985</risdate><volume>143</volume><issue>5</issue><spage>616</spage><epage>621</epage><pages>616-621</pages><issn>0093-0415</issn><eissn>1476-2978</eissn><coden>WJMDA2</coden><abstract>In a Canadian multicenter trial, a new dosing regimen of cimetidine (Tagamet)—600 mg given twice a day—was compared with the standard regimen of 300 mg four times a day in 118 evaluable patients with endoscopically proved esophagitis. More than 90% of the patients evaluated had clinically moderate to severe esophagitis. After four weeks of therapy, both regimens had significantly reduced the number of episodes and the severity and duration of the worst episodes of daytime and nighttime heartburn, as evaluated by visual analogue scales. After eight weeks of therapy, this improvement persisted. There was no difference between the regimens. Healing was observed endoscopically in 57% of patients receiving cimetidine 300 mg four times a day and in 55% of those receiving 600 mg twice a day. Side effects were infrequent and minor.</abstract><cop>United States</cop><pub>BMJ Publishing Group LTD</pub><pmid>3909640</pmid><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0093-0415 |
| ispartof | The Western journal of medicine, 1985-11, Vol.143 (5), p.616-621 |
| issn | 0093-0415 1476-2978 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1306424 |
| source | MEDLINE; PubMed Central |
| subjects | Adult Cimetidine - administration & dosage Cimetidine - adverse effects Cimetidine - therapeutic use Clinical Investigation Clinical Trials as Topic Drug Administration Schedule Esophagitis - diagnosis Esophagitis - drug therapy Esophagoscopy Female Gastroesophageal Reflux - drug therapy Humans Male Middle Aged Random Allocation Time Factors |
| title | Cimetidine Therapy for Gastroesophageal Reflux Disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T09%3A35%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cimetidine%20Therapy%20for%20Gastroesophageal%20Reflux%20Disease&rft.jtitle=The%20Western%20journal%20of%20medicine&rft.au=Archambault,%20Andr%C3%A9%20P.&rft.date=1985-11-01&rft.volume=143&rft.issue=5&rft.spage=616&rft.epage=621&rft.pages=616-621&rft.issn=0093-0415&rft.eissn=1476-2978&rft.coden=WJMDA2&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E3993295631%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1774914819&rft_id=info:pmid/3909640&rfr_iscdi=true |